Want to see NAMS full AI Analyst Report?
NAMS Stock Chart & Stats
$34.68
-$0.03(-0.12%)
At close: 4:00 PM EST
$34.68
-$0.03(-0.12%)
Day’s Range― - ―
52-Week Range$17.63 - $42.21
Previous CloseN/A
Volume118.30K
Average Volume (3M)1.54M
Market Cap
$3.49B
Enterprise Value$3.07B
Total Cash (Recent Filing)$636.11M
Total Debt (Recent Filing)$23.00K
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 12, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding116,903,980
10 Day Avg. Volume1,037,931
30 Day Avg. Volume1,541,874
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)5.87
Price to Sales (P/S)178.34
P/FCF Ratio-27.11
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue135.92
Enterprise Value/Gross Profit139.37
Enterprise Value/Ebitda-14.43
Forecast
1Y Price Target
$48.43Price Target Upside39.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.81
Revenue Forecast (FY)$29.47M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low debt and a large equity base give NewAmsterdam material financial flexibility to fund ongoing clinical programs and absorb trial timing variability. This solvency reduces bankruptcy risk, supports strategic partnerships or licensing negotiations, and lengthens the runway before dilutive capital is required.
Very High Gross MarginsVery high reported gross margin reflects low product/COGS intensity for the company’s therapeutic candidates and suggests favorable unit economics if obicetrapib or other assets commercialize. Durable high gross margins would enable scalable profitability once fixed R&D and commercial investments are covered by revenue.
Improved Governance And Employee AlignmentShareholder approval of an ESPP and continuity of board/auditor appointments strengthen retention, alignment and governance over the medium term. Extended issuance authority also gives management controlled flexibility to raise equity when strategically needed to fund trials or partnerships without disorderly capital constraints.
Bears Say
High Cash BurnSustained ~-$142M annual cash outflow materially shortens the company’s financing runway absent new funds or partnerships. Persistent burn forces frequent capital raises or licensing deals, raising dilution and execution risk and constraining long-term planning for multi-year clinical programs unless offset by financings or large collaborations.
Deep Persistent LossesExtremely negative net margins reflect that operating costs far exceed current revenue and are likely structural until regulatory approval and commercialization. Persistent losses depress returns on equity and require ongoing external funding, increasing dependency on successful trial outcomes to justify further investment.
Small, Volatile Revenue BaseA limited and unstable revenue stream cannot absorb fixed R&D and G&A cost structure, leaving profitability highly contingent on future approvals or partnerships. Revenue volatility undermines forecasting, increases financing frequency, and heightens the impact of any clinical or regulatory setbacks on long-term viability.
NewAmsterdam Pharma Company News
NAMS FAQ
What was Newamsterdam Pharma Company N.V.’s price range in the past 12 months?
Newamsterdam Pharma Company N.V. lowest stock price was $17.63 and its highest was $42.20 in the past 12 months.
What is Newamsterdam Pharma Company N.V.’s market cap?
Newamsterdam Pharma Company N.V.’s market cap is $3.49B.
When is Newamsterdam Pharma Company N.V.’s upcoming earnings report date?
Newamsterdam Pharma Company N.V.’s upcoming earnings report date is Aug 12, 2026 which is in 41 days.
How were Newamsterdam Pharma Company N.V.’s earnings last quarter?
Newamsterdam Pharma Company N.V. released its earnings results on May 07, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.459 by $0.059.
Is Newamsterdam Pharma Company N.V. overvalued?
According to Wall Street analysts Newamsterdam Pharma Company N.V.’s price is currently Undervalued.
Does Newamsterdam Pharma Company N.V. pay dividends?
Newamsterdam Pharma Company N.V. does not currently pay dividends.
What is Newamsterdam Pharma Company N.V.’s EPS estimate?
Newamsterdam Pharma Company N.V.’s EPS estimate is -0.48.
How many shares outstanding does Newamsterdam Pharma Company N.V. have?
Newamsterdam Pharma Company N.V. has 116,903,980 shares outstanding.
What happened to Newamsterdam Pharma Company N.V.’s price movement after its last earnings report?
Newamsterdam Pharma Company N.V. reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.459. Following the earnings report the stock price went up 12.456%.
Which hedge fund is a major shareholder of Newamsterdam Pharma Company N.V.?
Currently, no hedge funds are holding shares in NAMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NewAmsterdam Pharma Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.43 (39.64% Upside)
$48.43 (39.64% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 386.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
87.13%
12-Months-Change
Fundamentals
Return on Equity
-29.80%
Trailing 12-Months
Asset Growth
-10.48%
Trailing 12-Months
Company Description
Newamsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NAMS Stock 12 Month Forecast
Average Price Target
$48.43
▲(39.64% Upside)
Technical Analysis
Ownership Overview
6.26% Insiders
22.10% Mutual Funds
20.47% Other Institutional Investors
49.50% Public Companies and
Individual Investors